CL2012003201A1 - Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina. - Google Patents

Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina.

Info

Publication number
CL2012003201A1
CL2012003201A1 CL2012003201A CL2012003201A CL2012003201A1 CL 2012003201 A1 CL2012003201 A1 CL 2012003201A1 CL 2012003201 A CL2012003201 A CL 2012003201A CL 2012003201 A CL2012003201 A CL 2012003201A CL 2012003201 A1 CL2012003201 A1 CL 2012003201A1
Authority
CL
Chile
Prior art keywords
fidaxomycin
cdi
combat
mammal
treating
Prior art date
Application number
CL2012003201A
Other languages
English (en)
Inventor
Youe-Kong Shue
Sherwood Gorbach
Pamela Sears
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of CL2012003201A1 publication Critical patent/CL2012003201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método para tratar una CDI en un mamífero que esta siendo sometido simultáneamente a una terapia con antibióticos para combatir una infección diferente, que comprende el uso de fidaxomicina.
CL2012003201A 2010-05-18 2012-11-16 Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina. CL2012003201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34591510P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
CL2012003201A1 true CL2012003201A1 (es) 2013-07-05

Family

ID=44992319

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003201A CL2012003201A1 (es) 2010-05-18 2012-11-16 Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina.

Country Status (9)

Country Link
US (1) US20130331347A1 (es)
AU (1) AU2011255630B2 (es)
BR (1) BR112012029259A8 (es)
CA (1) CA2799386A1 (es)
CL (1) CL2012003201A1 (es)
CO (1) CO6670518A2 (es)
MX (1) MX2012013374A (es)
PE (1) PE20130310A1 (es)
WO (1) WO2011146621A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140887A1 (es) * 2011-02-04 2014-08-14 Optimer Pharmaceuticals Inc Tratamiento de infecciones bacterianas
WO2014135891A1 (en) * 2013-03-08 2014-09-12 Cipla Limited Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103920017B (zh) * 2014-05-09 2016-08-17 马金风 一种治疗宫颈炎的药物组合物
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713954T3 (es) * 2004-05-14 2019-05-24 Merck Sharp & Dohme Tratamiento de enfermedades asociadas al uso de antibióticos
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
US20130331347A1 (en) 2013-12-12
AU2011255630B2 (en) 2015-04-30
CA2799386A1 (en) 2011-11-24
WO2011146621A2 (en) 2011-11-24
PE20130310A1 (es) 2013-04-06
BR112012029259A2 (pt) 2021-03-02
BR112012029259A8 (pt) 2021-03-23
CO6670518A2 (es) 2013-05-15
WO2011146621A9 (en) 2012-04-12
MX2012013374A (es) 2013-05-06
AU2011255630A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
AR089993A1 (es) Macrociclos peptidomimeticos
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
CL2012003385A1 (es) Tratamiento para la incontinencia.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
PE20211094A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX386224B (es) Activadores de cinasa de piruvato para su uso en terapia.
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
CO7020912A2 (es) Inhibidores de bromodominios
PE20151604A1 (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
MX391175B (es) Macrociclos peptidomimeticos.
BR112013029773A2 (pt) canabinoides para uso no tratamento de dor neuropática
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112014004937A2 (pt) método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
ES2723827T3 (es) Terapia de combinación de fármacos para el tratamiento de tumores sólidos
MX345351B (es) Compuesto macrociclico y metodos para su produccion.
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА